Data/hora: 04/06/2024 10:25:02

Provedor de dados: 	Brazilian Journal of Infectious Diseases	
País: 	Brazil	
Título: 	Demographic and anthropometrical analysis and genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil	
Autores: 	Focaccia,R.; Baraldo,D.C.M.; Ferraz,M.L.G.; Martinelli,A.L.C.; Carrilho,F.J.; Gonçales Jr.,F.L.; Pedroso,M.L.A.; Coelho,H.S.M.; Lacerda,M.A.; Brandão,C.E.; Mattos,A.A.; Lira,L.G.C.; Zamin Jr.,I.; Pinheiro,J.O.P.; Tovo,C.V.; Both,C.T.; Soares,J.A.S.; Dittrich,S.	
Data: 	2004-10-01	
Ano: 	2004	
Palavras-chave: 	HCV; Chronic hepatitis C; Genotype; Body weight; Brazil.	
Resumo: 	Hepatitis C virus (HCV) infection is a serious public health problem, since 80% to 85% of HCV carriers develop a persistent infection that can progress into liver cirrhosis and hepatocarcinoma. Considering that the response of hepatitis C patients to combination therapy with interferon and ribavirin depends on HCV characteristics as well as on host features, we made a retrospective analysis of demographic and anthropometrical data and HCV genotype distribution of chronic hepatitis C patients treated in public and private reference centers in Brazil. The medical records of 4,996 patients were reviewed, 81% from public and 19% from private institutions. Patients' median age was 46 years, and there was a higher prevalence of male (62%) and white patients (80%). The analysis of HCV-infecting strains showed a predominance of genotype 1 (64%) over genotypes 2 and 3. The patients' mean weight was 70.6 kg, and 65% of the patients weighed less than 77kg. Overweight and obesity were observed in 37.8% and 13.6% of the patients, respectively. Since a body weight of 75 kg or less has been considered an independent factor that significantly increases the odds of achieving a sustained virological response, the Brazilian population seems to have a more favorable body weight profile to achieve a sustained response than the American and European populations. The finding that 65% of chronic hepatitis C patients have a body weight of 77 kg or less may have a positive pharmacoeconomic impact on the treatment of genotype 1 HCV patients with weight-based doses of peginterferon.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000500003	
Editor: 	Brazilian Society of Infectious Diseases	
Relação: 	10.1590/S1413-86702004000500003	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Infectious Diseases  v.8 n.5 2004	
Fonte: 	info:eu-repo/semantics/openAccess